ArticleFrontiers in medicine2022
Trends in Uveal Melanoma Presentation and Survival During Five Decades: A Nationwide Survey of 3898 Swedish Patients.
Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Tumour control, eye retention and visual acuity after radiotherapy for choroidal melanoma.BMJ open ophthalmology · 2026Article
- Custom bipolar electrode for bleomycin-based electrochemotherapy in patient-derived uveal melanomaFrontiers in cell and developmental biology · 2026Article
- Identification of two distinct uveal melanoma subtypes based on the immune cell infiltration of the primary tumour.Cancer immunology, immunotherapy : CII · 2025Article
- Article
- Management of liver metastases from uveal melanoma.The British journal of surgery · 2025Review
- Article
- Incidence, risk factors and outcomes of cataract surgery after plaque brachytherapy for posterior uveal melanoma.Heliyon · 2024Article
- Comprehensive causes of death in uveal melanoma: mortality in 1530 consecutively diagnosed patients followed until death.JNCI cancer spectrum · 2023Article
- Worldwide Incidence of Ocular Melanoma and Correlation With Pigmentation-Related Risk Factors.Investigative ophthalmology & visual science · 2023Article
- Increasing demand for ophthalmic pathology: time trends in a laboratory with nationwide coverage.BMC ophthalmology · 2023Article
- The prognostic implication of latitude in uveal melanoma: a nationwide observational cohort study of all patients born in Sweden between 1947 and 1989.Discover oncology · 2022Article
- Uveal melanoma incidence trends in Canada: 1992-2010 vs. 2011-2017.Frontiers in medicine · 2022Article
- Global incidence and prevalence in uveal melanoma.Advances in ophthalmology practice and researchArticle
- Development and Validation of a Deep Learning Algorithm for Differentiation of Choroidal Nevi from Small Melanoma in Fundus Photographs.Ophthalmology scienceArticle
- A Prognostic Score for the Prediction of Local Treatment Failure in Plaque Brachytherapy of Uveal Melanoma.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In contrast to most other cancers, uveal melanoma (UM) is characterized by an absence of major improvements in patient survival during the last several decades. In this study, we examine changes in incidence rates, patient age and tumor size at diagnosis, treatment practices and survival for patients diagnosed in Sweden during the period 1960-2010. Methods: All patients diagnosed with posterior UM between January 1st, 1960, and December 31st, 2009, in Sweden, were included ( Results: Crude (6.5-11.6 cases/million/year) and age-standardized incidence rates (5.6-9.6 cases/million/year) varied between individual years during the study period, but both had a stable linear trend overall ( Conclusion: In the period from 1960-2010, crude and age-standardized incidence rates of UM have remained stable in Sweden. Several other aspects have changed: Plaque brachytherapy with ruthenium-106 has replaced enucleation as the most common primary treatment modality; patients have become older and their tumors smaller at the time of diagnosis; and their survival has improved. This might indicate a beneficial survival effect of earlier diagnosis and treatment, but the potential influence from lead-time bias should be taken into consideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.